Introduction Concurrent chemoradiation is the standard of care for women with locoregionally advanced cancer of the cervix. The disease and treatment can affect the quality of Life (QOL). The study aimed to determine the adverse events and quality of life of these patients.

Methods A prospective longitudinal study was conducted at our institution in patients with histologically confirmed carcinoma cervix undergoing radical concurrent chemoradiotherapy. Patients with severe physical or mental disabilities and those who developed recurrence in the follow-up period were excluded from further formal interviews. Ninety-five patients were enrolled from 1^st April 2021 to 31^st April 2022. The NCI Common Terminology Criteria for Adverse Events v 5.0 were completed at weeks 0,1,3, at brachytherapy, at 3 and 6 months. The EORTC QLQ-C30 and QLQ-CX24 questionnaires were administered at week 0, at brachytherapy, at three months, and at six months.

Results The lowest global quality of life scores were recorded during treatment, with the highest scores six months post-treatment. Physical, role and social functioning declined during treatment but improved later, while emotional functioning scales were lowest at the beginning of treatment but improved significantly during treatment and follow-up. Body image declined during radiotherapy, and sexual worries increased with a decline in sexual and vaginal functioning post-treatment. The most common acute toxicities were fatigue, diarrhoea, nausea, anaemia, and leukopenia, while constipation, vaginal dryness, and dyspareunia were the most common late toxicities reported.

Conclusion/Implications These results can help healthcare providers better manage symptoms and improve outcomes for patients with advanced cervical cancer undergoing concurrent chemoradiotherapy.